Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

INCREASED CHITOTRIOSIDASE IS ASSOCIATED WITH ASPERGILLUS AND FREQUENT EXACERBATIONS IN SOUTH-EAST ASIANS WITH BRONCHIECTASIS.

Poh TY, Tiew PY, Hou Lim AY, Thng KX, Binte Mohamed Ali NA, Narayana JK, Aogáin MM, Tien Z, Chew WM, Wai Chan AK, Keir HR, Dicker AJ, Hassan TM, Xu H, Tee AKH, Ong TH, Koh MS, Abisheganaden JA, Chalmers JD, Chotirmall SH.

Chest. 2020 Mar 14. pii: S0012-3692(20)30446-3. doi: 10.1016/j.chest.2020.02.048. [Epub ahead of print]

PMID:
32184111
2.

Development and Reporting of Prediction Models: Guidance for Authors From Editors of Respiratory, Sleep, and Critical Care Journals.

Leisman DE, Harhay MO, Lederer DJ, Abramson M, Adjei AA, Bakker J, Ballas ZK, Barreiro E, Bell SC, Bellomo R, Bernstein JA, Branson RD, Brusasco V, Chalmers JD, Chokroverty S, Citerio G, Collop NA, Cooke CR, Crapo JD, Donaldson G, Fitzgerald DA, Grainger E, Hale L, Herth FJ, Kochanek PM, Marks G, Moorman JR, Ost DE, Schatz M, Sheikh A, Smyth AR, Stewart I, Stewart PW, Swenson ER, Szymusiak R, Teboul JL, Vincent JL, Wedzicha JA, Maslove DM.

Crit Care Med. 2020 Mar 4. doi: 10.1097/CCM.0000000000004246. [Epub ahead of print]

PMID:
32141923
3.

The Relationship Between Symptoms, Exacerbations and Treatment Response in Bronchiectasis.

Gao YH, Abo Leyah H, Finch S, Lonergan M, Aliberti S, De Soyza A, Fardon TC, Tino G, Chalmers JD.

Am J Respir Crit Care Med. 2020 Feb 25. doi: 10.1164/rccm.201910-1972OC. [Epub ahead of print]

PMID:
32097051
4.

Is bronchiectasis really a disease?

Shteinberg M, Flume PA, Chalmers JD.

Eur Respir Rev. 2020 Jan 29;29(155). pii: 190051. doi: 10.1183/16000617.0051-2019. Print 2020 Mar 31. Erratum in: Eur Respir Rev. 2020 Feb 12;29(155):.

5.

Managing and preventing exacerbation of bronchiectasis.

Abo-Leyah H, Chalmers JD.

Curr Opin Infect Dis. 2020 Apr;33(2):189-196. doi: 10.1097/QCO.0000000000000628.

PMID:
31990814
6.

The evolution of the European Respiratory Journal: ready for the new decade!

Chalmers JD, Reeves EL, Bullen NJ, Kolb M.

Eur Respir J. 2020 Jan 23;55(1). pii: 1902503. doi: 10.1183/13993003.02503-2019. Print 2020 Jan. No abstract available.

PMID:
31974124
7.

Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST).

Artaraz A, Crichton ML, Finch S, Abo-Leyah H, Goeminne P, Aliberti S, Fardon T, Chalmers JD.

Respir Res. 2020 Jan 13;21(1):18. doi: 10.1186/s12931-019-1272-y.

8.

Happy Birthday, Bronchiectasis: 200 Years of Targeting Mucus.

Chalmers JD, Sibila O.

Am J Respir Crit Care Med. 2020 Mar 15;201(6):639-640. doi: 10.1164/rccm.201911-2261ED. No abstract available.

9.

Assessment of Phenotype Microarray plates for rapid and high-throughput analysis of collateral sensitivity networks.

Dunkley EJ, Chalmers JD, Cho S, Finn TJ, Patrick WM.

PLoS One. 2019 Dec 18;14(12):e0219879. doi: 10.1371/journal.pone.0219879. eCollection 2019.

10.

Validation of the COPD Assessment Test (CAT) as an Outcome Measure in Bronchiectasis.

Finch S, Laska IF, Abo-Leyah H, Fardon TC, Chalmers JD.

Chest. 2019 Nov 12. pii: S0012-3692(19)34198-4. doi: 10.1016/j.chest.2019.10.030. [Epub ahead of print]

PMID:
31730832
11.

Recommendations for travelling with bronchiectasis: a joint ELF/EMBARC/ERN-Lung collaboration.

Shteinberg M, Crossley B, Lavie T, Nadler S, Boyd J, Ringshausen FC, Aksamit T, Chalmers JD, Goeminne P.

ERJ Open Res. 2019 Oct 30;5(4). pii: 00113-2019. doi: 10.1183/23120541.00113-2019. eCollection 2019 Oct.

12.

Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review.

Langham S, Lewis J, Pooley N, Embleton N, Langham J, Han MK, Chalmers JD.

Respir Res. 2019 Nov 4;20(1):242. doi: 10.1186/s12931-019-1213-9. Review.

13.

The impact of certain underlying comorbidities on the risk of developing hospitalised pneumonia in England.

Campling J, Jones D, Chalmers JD, Jiang Q, Vyse A, Madhava H, Ellsbury G, Slack M.

Pneumonia (Nathan). 2019 Oct 11;11:4. doi: 10.1186/s41479-019-0063-z. eCollection 2019.

14.

Evaluation of active neutrophil elastase in sputum of bronchiectasis and cystic fibrosis patients: A comparison among different techniques.

Oriano M, Terranova L, Sotgiu G, Saderi L, Bellofiore A, Retucci M, Marotta C, Gramegna A, Miglietta D, Carnini C, Marchisio P, Chalmers JD, Aliberti S, Blasi F.

Pulm Pharmacol Ther. 2019 Dec;59:101856. doi: 10.1016/j.pupt.2019.101856. Epub 2019 Oct 15.

PMID:
31626976
15.

The microbiome in bronchiectasis: Cutting a lung story short.

Smith AH, Chalmers JD.

Respirology. 2020 Jan;25(1):43-44. doi: 10.1111/resp.13697. Epub 2019 Oct 6. No abstract available.

16.

Cystic fibrosis lung disease and bronchiectasis.

Chalmers JD.

Lancet Respir Med. 2020 Jan;8(1):12-14. doi: 10.1016/S2213-2600(19)30335-2. Epub 2019 Sep 27. No abstract available.

PMID:
31570316
17.

Respiratory physiotherapy in the bronchiectasis guidelines: is there a loud voice we are yet to hear?

Spinou A, Chalmers JD.

Eur Respir J. 2019 Sep 28;54(3). pii: 1901610. doi: 10.1183/13993003.01610-2019. Print 2019 Sep. No abstract available.

PMID:
31563873
18.

The microbiome in bronchiectasis.

Richardson H, Dicker AJ, Barclay H, Chalmers JD.

Eur Respir Rev. 2019 Sep 4;28(153). pii: 190048. doi: 10.1183/16000617.0048-2019. Print 2019 Sep 30. Review.

19.

Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1).

Loebinger MR, Polverino E, Blasi F, Elborn SJ, Chalmers JD, Tiddens HA, Goossens H, Tunney M, Zhou W, Angyalosi G, Hill AT, Haworth CS; iBEST-1 Trial Team.

Pulm Pharmacol Ther. 2019 Oct;58:101834. doi: 10.1016/j.pupt.2019.101834. Epub 2019 Aug 18.

PMID:
31433997
20.

Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis.

Chalmers JD, Boersma W, Lonergan M, Jayaram L, Crichton ML, Karalus N, Taylor SL, Martin ML, Burr LD, Wong C, Altenburg J.

Lancet Respir Med. 2019 Oct;7(10):845-854. doi: 10.1016/S2213-2600(19)30191-2. Epub 2019 Aug 9.

PMID:
31405828
21.

The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis.

Laska IF, Crichton ML, Shoemark A, Chalmers JD.

Lancet Respir Med. 2019 Oct;7(10):855-869. doi: 10.1016/S2213-2600(19)30185-7. Epub 2019 Aug 9.

PMID:
31405826
22.

Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry.

Dhar R, Singh S, Talwar D, Mohan M, Tripathi SK, Swarnakar R, Trivedi S, Rajagopala S, D'Souza G, Padmanabhan A, Baburao A, Mahesh PA, Ghewade B, Nair G, Jindal A, Jayadevappa GDH, Sawhney H, Sarmah KR, Saha K, Anantharaj S, Khanna A, Gami S, Shah A, Shah A, Dutt N, Garg H, Vyas S, Venugopal K, Prasad R, Aleemuddin NM, Karmakar S, Singh V, Jindal SK, Sharma S, Prajapat D, Chandrashekaria S, McDonnell MJ, Mishra A, Rutherford R, Ramanathan RP, Goeminne PC, Vasudev P, Dimakou K, Crichton ML, Jayaraj BS, Kungwani R, Das A, Sawhney M, Polverino E, Torres A, Gulecha NS, Shteinberg M, De Soyza A, Mangala A, Shah P, Chauhan NK, Jajodia N, Singhal A, Batra S, Hasan A, Limaye S, Salvi S, Aliberti S, Chalmers JD.

Lancet Glob Health. 2019 Sep;7(9):e1269-e1279. doi: 10.1016/S2214-109X(19)30327-4. Erratum in: Lancet Glob Health. 2019 Dec;7(12):e1621.

23.

Treatment to prevent exacerbations in bronchiectasis: macrolides as first line?

Laska IF, Chalmers JD.

Eur Respir J. 2019 Jul 18;54(1). pii: 1901213. doi: 10.1183/13993003.01213-2019. Print 2019 Jul. No abstract available.

PMID:
31320480
24.

Same meat, different gravy: ignore the new names of mycobacteria.

Tortoli E, Brown-Elliott BA, Chalmers JD, Cirillo DM, Daley CL, Emler S, Floto RA, Garcia MJ, Hoefsloot W, Koh WJ, Lange C, Loebinger M, Maurer FP, Morimoto K, Niemann S, Richter E, Turenne CY, Vasireddy R, Vasireddy S, Wagner D, Wallace RJ Jr, Wengenack N, van Ingen J.

Eur Respir J. 2019 Jul 11;54(1). pii: 1900795. doi: 10.1183/13993003.00795-2019. Print 2019 Jul. No abstract available.

PMID:
31296783
25.

Antimicrobial peptides, disease severity and exacerbations in bronchiectasis.

Sibila O, Perea L, Cantó E, Shoemark A, Cassidy D, Smith AH, Suarez-Cuartin G, Rodrigo-Troyano A, Keir HR, Oriano M, Ong S, Vidal S, Blasi F, Aliberti S, Chalmers JD.

Thorax. 2019 Sep;74(9):835-842. doi: 10.1136/thoraxjnl-2018-212895. Epub 2019 Jul 5.

PMID:
31278172
26.

Pregnancy Zone Protein Is Associated with Airway Infection, Neutrophil Extracellular Trap Formation, and Disease Severity in Bronchiectasis.

Finch S, Shoemark A, Dicker AJ, Keir HR, Smith A, Ong S, Tan B, Choi JY, Fardon TC, Cassidy D, Huang JTJ, Chalmers JD.

Am J Respir Crit Care Med. 2019 Oct 15;200(8):992-1001. doi: 10.1164/rccm.201812-2351OC.

27.

Response.

Chalmers JD.

Chest. 2019 Jun;155(6):1302-1303. doi: 10.1016/j.chest.2019.02.316. No abstract available.

PMID:
31174643
28.

A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation.

Shoemark A, Cant E, Carreto L, Smith A, Oriano M, Keir HR, Perea L, Canto E, Terranova L, Vidal S, Moffitt K, Aliberti S, Sibila O, Chalmers JD.

Eur Respir J. 2019 Jun 13;53(6). pii: 1900303. doi: 10.1183/13993003.00303-2019. Print 2019 Jun.

29.

Airway Bacterial Load and Inhaled Antibiotic Response in Bronchiectasis.

Sibila O, Laserna E, Shoemark A, Keir HR, Finch S, Rodrigo-Troyano A, Perea L, Lonergan M, Goeminne PC, Chalmers JD.

Am J Respir Crit Care Med. 2019 Jul 1;200(1):33-41. doi: 10.1164/rccm.201809-1651OC.

PMID:
31109172
30.

Rheumatoid arthritis-associated bronchiectasis - Authors' reply.

Flume PA, Chalmers JD, Olivier KN.

Lancet. 2019 May 18;393(10185):2036. doi: 10.1016/S0140-6736(19)30012-1. No abstract available.

PMID:
31106746
31.

Pulmonary rehabilitation after exacerbation of bronchiectasis: a pilot randomized controlled trial.

Chalmers JD, Crichton ML, Brady G, Finch S, Lonergan M, Fardon TC.

BMC Pulm Med. 2019 May 6;19(1):85. doi: 10.1186/s12890-019-0856-0.

32.

Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection.

VanDevanter DR, Gonda I, Dahms J, Cipolla D, Davis AM, Chalmers JD, Froehlich J.

Clin Microbiol Infect. 2019 Dec;25(12):1532-1538. doi: 10.1016/j.cmi.2019.04.017. Epub 2019 Apr 26.

PMID:
31035017
33.

Bronchiectasis Guidelines-Recommendations Into Practice.

Redondo M, Chalmers JD.

Arch Bronconeumol. 2019 Jun;55(6):286-288. doi: 10.1016/j.arbres.2018.10.012. Epub 2019 Apr 10. English, Spanish. No abstract available.

PMID:
30981551
34.

Personalised anti-inflammatory therapy for bronchiectasis and cystic fibrosis: selecting patients for controlled trials of neutrophil elastase inhibition.

Keir HR, Fong CJ, Crichton ML, Barth P, Chevalier E, Brady G, Kennedy G, Zimmermann J, Bruijnzeel PLB, Dicker AJ, Chalmers JD.

ERJ Open Res. 2019 Mar 25;5(1). pii: 00252-2018. doi: 10.1183/23120541.00252-2018. eCollection 2019 Feb.

35.

A systematic review of pharmacotherapeutic clinical trial end-points for bronchiectasis in adults.

Crichton ML, Aliberti S, Chalmers JD.

Eur Respir Rev. 2019 Mar 14;28(151). pii: 180108. doi: 10.1183/16000617.0108-2018. Print 2019 Mar 31.

36.

The economic burden of bronchiectasis - known and unknown: a systematic review.

Goeminne PC, Hernandez F, Diel R, Filonenko A, Hughes R, Juelich F, Solomon GM, Upton A, Wichmann K, Xu W, Chalmers JD.

BMC Pulm Med. 2019 Feb 28;19(1):54. doi: 10.1186/s12890-019-0818-6.

37.

Reply: More on Causal Inference Studies.

Lederer DJ, Bell SC, Smyth AR, Chalmers JD.

Ann Am Thorac Soc. 2019 May;16(5):646. doi: 10.1513/AnnalsATS.201901-070LE. No abstract available.

38.

Challenges in severe community-acquired pneumonia: a point-of-view review.

Torres A, Chalmers JD, Dela Cruz CS, Dominedò C, Kollef M, Martin-Loeches I, Niederman M, Wunderink RG.

Intensive Care Med. 2019 Feb;45(2):159-171. doi: 10.1007/s00134-019-05519-y. Epub 2019 Jan 31. Review.

39.

British Thoracic Society guideline for bronchiectasis in adults.

Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn JS, Floto RA, Grillo L, Gruffydd-Jones K, Harvey A, Haworth CS, Hiscocks E, Hurst JR, Johnson C, Kelleher WP, Bedi P, Payne K, Saleh H, Screaton NJ, Smith M, Tunney M, Whitters D, Wilson R, Loebinger MR.

BMJ Open Respir Res. 2018 Dec 28;5(1):e000348. doi: 10.1136/bmjresp-2018-000348. eCollection 2018.

40.

Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.

Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, Thompson B, Wanner A, O'Donnell AE.

Lancet Respir Med. 2019 Mar;7(3):213-226. doi: 10.1016/S2213-2600(18)30427-2. Epub 2019 Jan 15. Erratum in: Lancet Respir Med. 2019 Jan 25;:.

PMID:
30658914
41.

The evolution of the European Respiratory Journal: volume 2.

Chalmers JD, Kolb M.

Eur Respir J. 2019 Jan 17;53(1). pii: 1802459. doi: 10.1183/13993003.02459-2018. Print 2019 Jan. No abstract available.

PMID:
30655453
42.

British Thoracic Society Guideline for bronchiectasis in adults.

Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn SJ, Floto AR, Grillo L, Gruffydd-Jones K, Harvey A, Haworth CS, Hiscocks E, Hurst JR, Johnson C, Kelleher PW, Bedi P, Payne K, Saleh H, Screaton NJ, Smith M, Tunney M, Whitters D, Wilson R, Loebinger MR.

Thorax. 2019 Jan;74(Suppl 1):1-69. doi: 10.1136/thoraxjnl-2018-212463. No abstract available.

PMID:
30545985
43.

The effect of changes to GOLD severity stage on long term morbidity and mortality in COPD.

Flynn RWV, MacDonald TM, Chalmers JD, Schembri S.

Respir Res. 2018 Dec 12;19(1):249. doi: 10.1186/s12931-018-0960-3.

44.

Economic burden of bronchiectasis in Germany.

Diel R, Chalmers JD, Rabe KF, Nienhaus A, Loddenkemper R, Ringshausen FC.

Eur Respir J. 2019 Feb 28;53(2). pii: 1802033. doi: 10.1183/13993003.02033-2018. Print 2019 Feb.

PMID:
30523162
45.

New Insights Into the Epidemiology of Bronchiectasis.

Chalmers JD.

Chest. 2018 Dec;154(6):1272-1273. doi: 10.1016/j.chest.2018.08.1051. No abstract available.

PMID:
30526964
46.

ERS syllabus for postgraduate training in respiratory infections: a guide for comprehensive training.

Aliberti S, Farr A, Tabin N, Blasi F, Torres A, Woodhead M, Migliori GB, Sotgiu G, Dimopoulos G, Chalmers JD, Ringshausen FC, Loebinger MR, Read R, Rohde G.

Breathe (Sheff). 2018 Dec;14(4):269-275. doi: 10.1183/20734735.026218.

47.

Quality control for multiple breath washout tests in multicentre bronchiectasis studies: Experiences from the BRONCH-UK clinimetrics study.

O'Neill K, Lakshmipathy GR, Ferguson K, Cosgrove D, Hill AT, Loebinger MR, Carroll M, Chalmers JD, Gatheral T, Johnson C, DeSoyza A, Hurst JR, Bradbury I, Elborn JS, Bradley JM.

Respir Med. 2018 Dec;145:206-211. doi: 10.1016/j.rmed.2018.10.030. Epub 2018 Nov 1.

PMID:
30509710
48.

A comprehensive approach to lung function in bronchiectasis.

Radovanovic D, Santus P, Blasi F, Sotgiu G, D'Arcangelo F, Simonetta E, Contarini M, Franceschi E, Goeminne PC, Chalmers JD, Aliberti S.

Respir Med. 2018 Dec;145:120-129. doi: 10.1016/j.rmed.2018.10.031. Epub 2018 Nov 2.

PMID:
30509700
49.

The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) ERS Clinical Research Collaboration.

Aliberti S, Polverino E, Chalmers JD, Altenburg J, Shteinberg M, Goeminne PC, Welte T, Shoemark A, Almagro M, Blasi F; EMBARC Clinical Research Collaboration.

Eur Respir J. 2018 Nov 29;52(5). pii: 1802074. doi: 10.1183/13993003.02074-2018. Print 2018 Nov. No abstract available.

PMID:
30498055
50.

Circulating desmosine as a biomarker of azithromycin treatment response: a post hoc analysis of the COLUMBUS randomised controlled trial.

Chalmers JD, Djamin RS, Schouten M, Keir HR, Tan B, Aerts JGJV, Huang JT, van der Eerden M.

ERJ Open Res. 2018 Nov 12;4(4). pii: 00136-2018. doi: 10.1183/23120541.00136-2018. eCollection 2018 Oct.

Supplemental Content

Loading ...
Support Center